Urology is a branch of medicine that deals with the diagnosis and treatment of diseases affecting the urinary tract of males and females, reproductive organs of males, as well as kidneys, ureters, bladder and prostate.
Urology is a wide-ranging speciality and deals with the diagnosis and treatment of conditions such as genitourinary cancers including prostate cancer, cystinosis including nephropathic cystinosis as well as benign prostatic hyperplasia, erectile dysfunction and kidney transplantation for end-stage renal disease.
Featured Learning Zones
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Related news and insights
Myovant Sciences announced that its New Drug Application (NDA) for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer has been accepted for Priority Review by the FDA.
Genentech/Roche announced that the Phase III IPATential150 study with RG 7440 (ipatasertib) plus Zytiga (abiraterone) plus prednisone met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumors had PTEN loss.
Myovant Sciences announced additional results from its Phase III HERO study of once-daily, oral TAK 385 (relugolix) (120 mg) in men with advanced prostate cancer in an oral presentation at the American Society of Clinical Oncology (ASCO)’s ASCO20 Virtual Scientific Program and simultaneous publication in the New England Journal of Medicine (NEJM).